Improvement in insulin sensitivity following a 1-year lifestyle intervention program in viscerally obese men: contribution of abdominal adiposity

被引:32
作者
Borel, Anne-Laure [1 ]
Nazare, Julie-Anne [1 ]
Smith, Jessica [1 ]
Almeras, Natalie [1 ]
Tremblay, Angelo [1 ,2 ]
Bergeron, Jean [3 ]
Poirier, Paul [1 ]
Despres, Jean-Pierre [1 ]
机构
[1] Ctr Rech Inst Univ Cardiol & Pneumol Quebec, Ste Foy, PQ G1V 4G5, Canada
[2] Univ Laval, Dept Social & Prevent Med, Div Kinesiol, Quebec City, PQ, Canada
[3] CHUL Res Ctr, Lipid Res Ctr, Quebec City, PQ, Canada
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2012年 / 61卷 / 02期
基金
加拿大健康研究院;
关键词
IMPAIRED GLUCOSE-TOLERANCE; BETA-CELL FUNCTION; WEIGHT-LOSS; METABOLIC SYNDROME; FASTING GLUCOSE; RISK-FACTORS; RESISTANCE; EXERCISE; FAT; TISSUE;
D O I
10.1016/j.metabol.2011.06.024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The objectives of the study were to quantify the effect of a 1-year healthy eating-physical activity/exercise lifestyle modification program on insulin sensitivity in viscerally obese men classified according to their glucose tolerance status and to evaluate the respective contributions of changes in body fat distribution vs changes in cardiorespiratory fitness (CRF) to the improvements in indices of plasma glucose/insulin homeostasis. Abdominally obese, dyslipidemic men (waist circumference >= 90 cm, triglycerides >= 1.69 mmol/L, and/or high-density lipoprotein cholesterol <1.03 mmol/L) were recruited. The 1-year intervention/evaluation was completed by 104 men. Body weight, composition, and fat distribution were assessed by dual-energy x-ray absorptiometry/computed tomography. Cardiorespiratory fitness and cardiometabolic risk profile were measured. After 1 year, insulin sensitivity improved in association with decreases in both visceral (VAT) and subcutaneous adiposity (SAT) as well as with the improvement in CRF, regardless of baseline glucose tolerance. Further analyses were performed according to changes in glucose tolerance status: improvement (group I, n = 39), no change (group N, n = 50), or worsening (group W, n = 15) after 1 year. Groups I and N improved their insulin sensitivity and their CRF, whereas group W did not, while losing less VAT than groups I and N. Multiple regressions showed that reduction in VAT was associated with an improvement in homeostasis model assessment of insulin resistance, whereas reduction in SAT was rather associated with improvement of the insulin sensitivity index of Matsuda. Changes in CRF were not independently associated with changes in indices of plasma glucose/insulin homeostasis. A 1-year lifestyle intervention improved plasma glucose/insulin homeostasis in viscerally obese men, including those with normal glucose tolerance status at baseline. Changes in SAT and VAT but not in CRF appeared to mediate these improvements. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:262 / 272
页数:11
相关论文
共 49 条
[1]   What is the best predictor of future type 2 diabetes? [J].
Abdul-Ghani, Muhammad A. ;
Williams, Ken ;
DeFronzo, Ralph A. ;
Stern, Michael .
DIABETES CARE, 2007, 30 (06) :1544-1548
[2]  
[Anonymous], ACSMS GUID EX TEST P
[3]  
[Anonymous], 2008, 2008 Physical Activity Guidelines for Americans
[4]   Inverse associations between muscle mass, strength, and the metabolic syndrome [J].
Atlantis, Evan ;
Martin, Sean A. ;
Haren, Matthew T. ;
Taylor, Anne W. ;
Wittert, Gary A. .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2009, 58 (07) :1013-1022
[5]   SUR UN DOSAGE RAPIDE DU CHOLESTEROL LIE AUX ALPHA-LIPOPROTEINES ET AUX BETA-LIPOPROTEINES DU SERUM [J].
BURSTEIN, M ;
SAMAILLE, J .
CLINICA CHIMICA ACTA, 1960, 5 (04) :609-609
[6]   USE OF POLYETHYLENE GLYCOL TO SEPARATE FREE AND ANTIBODY-BOUND PEPTIDE HORMONES IN RADIOIMMUNOASSAYS [J].
DESBUQUOIS, B ;
AURBACH, GD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1971, 33 (05) :732-+
[7]   Abdominal obesity and metabolic syndrome [J].
Despres, Jean-Pierre ;
Lemieux, Isabelle .
NATURE, 2006, 444 (7121) :881-887
[8]   Effect of Rimonabant on the High-Triglyceride/Low-HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat The ADAGIO-Lipids Trial [J].
Despres, Jean-Pierre ;
Ross, Robert ;
Boka, Gabor ;
Almeras, Natalie ;
Lemieux, Isabelle .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2009, 29 (03) :416-423
[9]   CB1 antagonists for obesity-what lessons have we learned from rimonabant? [J].
Di Marzo, Vincenzo ;
Despres, Jean-Pierre .
NATURE REVIEWS ENDOCRINOLOGY, 2009, 5 (11) :633-638
[10]   Impact of weight-loss medications on the cardiovascular system - Focus on current and future anti-obesity drugs [J].
Drolet, Benoit ;
Simard, Chantale ;
Poirier, Paul .
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2007, 7 (04) :273-288